When Zachary Chaffin, an assistant clinical professor at UC Davis, began studying diabetic ketoacidosis, it was because he couldn't forget what he'd witnessed in the clinic: children developing severe brain swelling during treatment for a condition many didn't even know they had. That haunting experience set him on a path to understand one of type 1 diabetes's most dangerous complications—and his work, published recently in BMJ Open Diabetes Research & Care, has uncovered something researchers never expected to find.
Diabetic ketoacidosis, or DKA, strikes when the body cannot produce insulin and blood sugar rises uncontrollably. The body then generates toxic molecules called ketones, triggering a cascade of organ failure and life-threatening symptoms. For many children, it's their first sign of type 1 diabetes. Yet despite decades of treating DKA in hospitals, scientists didn't fully understand why some patients recovered with no lasting effects while others developed kidney disease, cognitive decline, or other severe complications years later.
That mystery drove Nicole Glaser, a professor and pediatric endocrinologist at UC Davis Health, and her team to do something no one had done before: comprehensively map the inflammatory molecules activated during DKA. Over two years, they analyzed blood samples from 123 children, many of them DKA patients, searching for the inflammatory signals coursing through the body during and after the crisis.
What they found was striking. The analyses revealed that DKA activates a broad spectrum of inflammatory molecules—cytokines, chemokines, and something called matrix metalloproteinases, or MMPs. These molecules don't simply spike during the acute crisis and vanish; they remain elevated for several days even after patients recover. But the most surprising discovery was how dominant MMPs became in this inflammatory storm. These proteins break down other proteins in the body, giving them extraordinary power to damage organs. "We were surprised to find MMPs playing such a dominant role," Glaser said, "and that could really help us."
The implications are profound. MMPs don't just circulate passively—they actively damage the kidneys and can breach the blood-brain barrier, the body's protective shield around the brain. Once that barrier is compromised, other inflammatory factors and toxic substances flood in, potentially causing the brain injury that Chaffin had witnessed firsthand in his young patients. Understanding MMPs' role could finally explain the mechanism behind DKA-related organ damage.
While this research won't immediately change how doctors treat DKA in emergency rooms, it opens a crucial door. Now that researchers understand which molecular players drive complications, they can develop targeted interventions. The findings could eventually help physicians identify which children face higher risk of long-term health consequences—allowing for earlier prevention or closer monitoring. Glaser's team is already refocusing its efforts, digging deeper into MMPs and how to control them.
"There's very little we can do to change the course of a disease without knowing why it happens," Glaser reflected. For the first time, thanks to work rooted in clinical experience and rigorous laboratory science, researchers have a clearer picture of what drives DKA's hidden damage. The path from understanding to healing has begun.